What changed: Ovarian cancer

When this page itself was last checked or edited.

Platinum-resistant PD-L1+ ovarian cancer

Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel

Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC

Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel

A milestone in how this cancer is treated.

First immunotherapy approval in ovarian cancer (February 2026).

NDA submitted (ROSELLA)

KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)

OS 18.

ORR 55.

OS 16.

A milestone in how this cancer is treated.

FRα+ platinum-resistant ovarian; 14 Nov 2024

ORR 44%, median PFS 19.

PFS HR 0.

OS 16.

First-line maintenance benefit confirmed while later-line PARP use retreats after OS imbalances (ARIEL4, SOLO3).

Accelerated approval, FRα-high platinum-resistant ovarian cancer (SORAYA)

FRα-high platinum-resistant ovarian cancer (full approval 2024)

PFS 20.

Accelerated approval; full approval after MIRASOL OS benefit in 2024.

A milestone in how this cancer is treated.

Intraoperative imaging of ovarian cancer lesions in adults

No significant reduction in ovarian cancer mortality.

A milestone in how this cancer is treated.

First-line ovarian maintenance, all-comers (PRIMA)

First-line maintenance with olaparib in HRD-positive ovarian cancer

Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer

First-line ovarian maintenance

OS 53.

Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer

PFS HR 0.

PFS HR 0.

PRIMA (niraparib, all comers) and PAOLA-1 (olaparib + bevacizumab, HRD-positive).

First-line maintenance in BRCA-mutated ovarian cancer (SOLO-1)

First-line ovarian cancer (GOG-0218)

Recurrent ovarian maintenance (ARIEL3)

First-line stage III-IV ovarian cancer after surgery

Maintenance in recurrent ovarian cancer after platinum response (now BRCA-mutated only)

OS 45.

PFS HR 0.

Two years of first-line olaparib maintenance (PFS HR 0.30) and HIPEC at interval surgery (OS +12 months) both reported.

Maintenance in platinum-sensitive recurrent ovarian cancer; tablet formulation

Maintenance in recurrent ovarian cancer regardless of BRCA (NOVA)

Recurrent ovarian cancer maintenance

Accelerated approval, gBRCA/sBRCA ovarian, ≥2 prior lines

BRCA-mutated advanced ovarian cancer after ≥2 chemotherapies (later narrowed)

gBRCA advanced ovarian cancer after ≥3 lines: first PARP inhibitor

Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy

Companion diagnostic for olaparib in germline BRCA-mutated advanced ovarian cancer

gBRCA ovarian cancer ≥3 lines

A milestone in how this cancer is treated.

For germline BRCA-mutated ovarian cancer after three lines.

GOG-0218 PFS 14.

A milestone in how this cancer is treated.

Relapsed platinum-sensitive ovarian cancer with PLD

Serous tubal intraepithelial carcinoma described in BRCA carriers' prophylactic specimens; leads to salpingectomy-based prevention.

NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC

Ovarian cancer with carboplatin

Farmer and Bryant papers in Nature set up the PARP inhibitor era.

Ovarian cancer refractory to platinum and paclitaxel

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.

Reduction of cumulative cisplatin renal toxicity in advanced ovarian cancer

BRCA2 in 1995; germline testing enters clinical practice over the next decade.

Refractory ovarian cancer

Ovarian cancer (now broad)

Persistent or recurrent ovarian cancer after first-line cisplatin or alkylating agent combinations

Ovarian cancer

Ovarian cancer (now broad use)

Testicular and ovarian cancer; bladder cancer 1993

First platinum responses in refractory disease; carboplatin follows in the 1980s.

Multiple myeloma; non-resectable epithelial ovarian carcinoma

Breast and ovarian adenocarcinoma; superficial papillary bladder carcinoma (intravesical); malignant effusions